5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Aarti Drugs Ltd.

•
aartidrugs.comBSE: 524348NSE: AARTIDRUGS
Market Cap₹ 3,871 Cr.
Current Price
High / Low₹ 535 / 319
Stock P/E22.6
Book Value₹ 159
Price to Book2.48
Dividend Yield0.47 %
ROCE13.5 %
ROE13.0 %
Face Value₹ 10

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.59x)
  • Company generates healthy free cash flow
  • Company comfortably covers its interest (7.2x coverage)
  • Company has a consistent dividend-paying track record
  • Company maintains a comfortable, low leverage position

CONS

  • Recent results are weak - TTM profit is down 22.6% versus prior year
  • Company has delivered a poor profit growth of 3.0% over past five years
  • Company has delivered a poor sales growth of 5.9% over past five years
  • Growth is decelerating - 3Y profit CAGR (-6.9%) trails the 5Y trend (3.0%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY MICROCAP250NIFTY TOTAL MKT
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.AARTIDRUGS424.1520.253871.220.4750.13-7.12702.7819.0113.1113.97
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
592578538560493543515623521579529632627
520512478490439484454534457504486552558
Operating Profit72656069546060896475427970
OPM %12.15%11.33%11.10%12.34%11.00%10.96%11.71%14.23%12.28%12.99%8.00%12.55%11.11%
11210011200112
Interest8878778776777
Depreciation12121212121212121214151515
Profit before Tax53474350354152714556225968
Tax %25.45%26.16%26.24%27.34%23.46%25.68%25.95%13.02%-7.52%25.10%-55.87%23.22%25.06%
Net Profit40353236273039614942344551
4.273.753.443.932.933.334.226.745.334.583.714.935.57

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
1,0751,0891,1401,4541,6351,9152,2512,4982,2672,1742,367
9009109551,2521,3871,5111,9302,2121,9981,9082,100
Operating Profit176179185203248404321286269265267
OPM %16.34%16.44%16.23%13.94%15.17%21.12%14.27%11.45%11.87%12.20%11.26%
041697524144
Interest4738364136262336333226
Depreciation3637384047484747484859
Profit before Tax93108112128175338255205192199204
Tax %28.60%29.97%34.58%31.63%22.46%23.69%23.68%25.39%26.29%20.85%15.92%
Net Profit66757387136258195153142157171
EPS27.3730.8430.6737.4214.5327.6521.0416.5015.4317.24—
Dividend Payout %24.66%3.16%3.21%2.70%3.43%9.04%4.75%6.06%6.48%5.80%—

COMPOUNDED SALES GROWTH

10 Years:
7%
5 Years:
6%
3 Years:
-1%

COMPOUNDED PROFIT GROWTH

10 Years:
7%
5 Years:
3%
3 Years:
-7%

STOCK PRICE CAGR

10 Years:
14%
5 Years:
-6%
3 Years:
-11%
1 Year:
-14%

RETURN ON EQUITY

10 Years:
20%
5 Years:
19%
3 Years:
13%
Last Year:
13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2020

Aug 17

Bonus issue

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Equity Capital24242424239393939291
3263634104955987668801,0221,0831,160
475460528481383340526648413470
Trade Payables164170240228316293416419393373
659911514514914412014190179
Total Liabilities1,0551,1161,3161,3731,4711,6372,0352,1952,1722,273
463542564586612631649634722761
Capital Work in Progress34142832111660161222273
11181719202428293042
167189254228307390488478442407
00000000644702
Cash & Bank5445442345
37534844950351757280789110882
Total Assets1,0551,1161,3161,3731,4711,6372,0352,1952,1722,273

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
14519484176233242120217337220
Cash from Investing-87-96-71-59-29-69-125-131-187-135
Cash from Financing-37-789-87-168-8584-31-149-85
1-0-01-1-0-1011

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
55.6755.6455.3855.4855.2254.7255.0355.0354.43
2.952.502.282.252.262.682.151.571.52
7.357.838.779.709.949.9010.1210.2210.29
Government0.000.000.000.000.000.000.000.000.00
34.0234.0233.5732.5732.5832.6932.7033.1833.75

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-03
Copy of Newspaper Publication

2026-09-03 - Aarti Drugs Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-02
Updates

2026-09-02 - Aarti Drugs Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for FY 2025-26 '.

2026-09-02
Shareholders meeting

2026-09-02 - Aarti Drugs Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 26, 2026

2026-09-01
Copy of Newspaper Publication

2026-09-01 - Aarti Drugs Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-27
Outcome of Board Meeting

2026-08-27 - Aarti Drugs Limited has informed the Exchange regarding Outcome of Board Meeting held on August 27, 2026.

2026-08-24
Trading Window

2026-08-24 - Aarti Drugs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

2026-08-14
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-14 - Aarti Drugs Limited has informed the Exchange about Schedule of meet

2026-08-10
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

2026-08-10 - Aarti Drugs Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company

2026-08-07
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-07 - Aarti Drugs Limited has informed the Exchange about Transcript

News

Recent coverage and analyst commentary for AARTIDRUGS

Loading news…

🤖

AI Stock Analyst

Aarti Drugs Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme


5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login